Amprion and Prema Cognition have announced a new collaboration to explore a more comprehensive approach to identifying and evaluating individuals at risk for neurodegenerative disease. The partnership combines Prema Cognition's PREMAZ digital cognitive assessment, which is designed to detect subtle changes in memory and cognitive performance, with Amprion's biomarker testing technologies that investigate the biological signs of neurodegenerative disease. Together, the companies aim to create a more seamless pathway from early cognitive screening to biomarker confirmation, helping support earlier and more informed clinical decision-making.
The collaboration is part of Amprion's broader Neuro-Convergence Initiative, which brings together biological, cognitive, and digital health technologies to better understand how neurodegenerative diseases develop and progress. PREMAZ, developed in collaboration with researchers at the University of Cambridge's Memory Lab, uses a novel approach that measures not only whether someone remembers information, but how precisely it is remembered. The tool is already being used in clinics across the United Kingdom, the United States, and India.
Initially, the companies plan to establish a patient assessment pathway where PREMAZ serves as an accessible front-end cognitive assessment that can help identify individuals who may benefit from further biomarker testing through Amprion's assays. Beyond clinical use, the partnership could also support research efforts, pharmaceutical development, and future advancements in neurodegenerative disease diagnostics.
As the field continues to move toward more personalized and proactive approaches to brain health, collaborations like this highlight the potential of combining digital tools and biomarker technologies to improve early detection and patient care.
Learn more about the partnership and its potential impact on neurodegenerative disease assessment.
